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Case Report: Concomitant Diagnosis
of Plasma Cell Leukemia in Patient
With JAK2 Positive Myeloproliferative
Neoplasm
Christine J. Kurian 1*, Colin Thomas 1, Sarah Houtmann 1, Thomas Klumpp 2 and
Adam Finn Binder 2
1Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States, 2Department of
Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, United States
Plasma cell dyscrasias and myeloproliferative neoplasms (MPN) are hematologic
malignancies arising from two distinct hematopoietic cell lineages. They rarely occur
concomitantly. Here, we report a case of a patient with a recent diagnosis of a JAK2
V617F positive MPN who presented with a new diagnosis of plasma cell leukemia.
The patient had presented to the hospital with a leukocytosis predominantly comprised
of plasma cells, followed by work-up involving peripheral blood flow cytometry, FISH
analysis, and bone-marrow biopsy. FISH analysis was suggestive of a common
progenitor cell for these distinct hematologic malignancies. To our knowledge, this case
represents the second reported instance of a concomitant JAK2 positive MPN with
primary plasma cell leukemia.
Keywords: case report, plasma cell leukemia, myeloproliferative neoplasm, JAK2 mutation,
essential thrombocytosis
INTRODUCTION
There are several published reports of patients with concomitant myeloproliferative neoplasms
(MPN) and plasma cell dyscrasias (PCD), the peculiarity of which being that these twomalignancies
arise from separate lineages in the hematopoietic ancestral tree (1, 2). Apart from case reports
of patients with MPNs and PCDs, one prospective study found the coexistence of monoclonal
gammopathy of undetermined significance (MGUS) in patients with a MPN to be 8.2%, which
is higher than the average prevalence of MGUS in the general population (3%) (3, 4).
Other studies, however, have not found a significantly higher proportion of MGUS in patients
with MPN—overall clouding the picture of this association (4). When patients are diagnosed with
plasma cell dyscrasia and an MPN, based on one case series, it seems the MPN either precedes
or is diagnosed concurrently with the plasma cell dyscrasia (5). Although bone marrow fibrosis is
common on diagnosis of MM, ∼38% of patients, it is likely a reactive process (5). There have been
a few reports of myelofibrosis in plasma cell leukemia; however, these have been presumed to be
reactive with negative JAK2 mutations (5, 6).
Unlike MGUS, smoldering myeloma, or multiple myeloma, primary plasma cell leukemia
(pPCL) has a distinct pathogenesis (7). pPCL is defined as de novo leukemia having >2 ×
109/L plasma cells in the peripheral blood or plasma cells making up >20% of peripheral blood
leukocytes. It is considered the most aggressive of all plasma cell neoplasms with poor overall
survival (8).
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Candoni et al. described a similar case in 2004 with a
case of plasma cell leukemia occurring in a patient with
thrombocythemia. At the time of his ET diagnosis, he was treated
with aspirin, hydroxyurea, and busulphan. In this patient’s PCL,
there was a high expression of P-glycoprotein and notably
his karyotype showed a deletion of chromosome 7 typically
associated with secondary leukemias. It was thought that his
previous cytoreductive therapy exposure with hydroxyurea and
busulphan may have contributed to the development of PCL (9).
Here, we report a another case of a patient with JAK2
V617F myeloproliferative syndrome, most likely essential
thrombocytosis (ET), and new diagnosis of plasma cell leukemia
(PCL): this is the second known reported case in the literature.
CASE DESCRIPTION
A 76-year-old Caucasian woman with a history of paroxysmal
atrial fibrillation, hypertension, chronic sciatica requiring
assistance with a walker, gastroesophageal reflux disease, and
a presumed diagnosis of JAK2 V617F positive ET initially
presented to an outside hospital with a left clavicular fracture
TABLE 1 | Temporal comparison of lab work from November 2018 (Nov-18), December 2018 (Dec-18), April 2019 (April-19), and May 2019 (May-19)—admission to
Thomas Jefferson University Hospital.
Variable Ref range Nov-18 Dec-18 April-19 May-19
Blood
White blood cell count (×103/mcL) 4.0–11.0 5.8 6.89 14.77 60.9
Neutrophils (%)-Auto 49–80 50.6 48.3 21
Lymphocytes (%)-Auto 13–43 32.9 35.7 48.1
Monocytes (%)-Auto 0.0–10 12.9 12.2 27.6
Basophils (%)-Auto 0.0–1.5 0.7 0.6 0.9
Eosinophis (%)-Auto 0.0–0.6 2.9 2.8 2
Plasma Cells (%)-Auto 0 0 0 0
Immature (%)-Auto 0.0–0.5 0 0.4 0.4
Neutrophils (%)-Manual 40–73 12
Lymphocytes (%)-Manual 20–44 22
Monocytes (%)-Manual 0–13 3
Basophils (%)-Manual 0–3 1
Eosinophils (%)-Manual 0–6 0
Plasma Cells (%)-Manual 0 60
Red-cell count (×106/mcL) 3.7–5.3 4.19 4.06 3.89 3.02
Hemoglobin (g/dL) 11.5–16.1 13.4 13.1 12.5 9.6
Hematocrit (%) 34–47.5 39.5 39.6 36.8 28.8
Mean corpuscular hemoglobin (pg) 28–35 32.0 32.3 32.1 31.8
Mean corpuscular volume (fL) 81–99 94.3 97.5 94.6 95
Platelet count (×103/mcL) 140–400 547 446 262 190
Iron (mcg/dL) 50–170 74
Iron binding capacity total (mcg/dL) 250–450 298
Ferritin (ng/mL) 8–252 65
C reactive protein (mg/dL) 0.0–0.9 <0.2
Sedimentation rate (mm/hr) 0.0–30 12
following a mechanical fall. The patient was incidentally found to
have a leukocytosis of 71,000 cells/mcL (66% lymphocytic). She
was transferred to Thomas Jefferson University Hospital (TJUH)
for further hematologic work-up.
In November of 2018, ∼6 months prior to admission
to TJUH, the patient received routine outpatient lab-work
showing a platelet count of 547,000 cell/mcL. At time of formal
hematological evaluation, her platelet count had decreased to
446,000 cell/mcL. She had no evidence of iron deficiency anemia
or positive markers for inflammation (Table 1). PCR analysis for
the JAK2V617F pointmutation was positive. She had a presumed
diagnosis of ET, although she did not have a bone marrow biopsy
at the time of diagnosis (10). Hydroxyurea was not started. Repeat
lab work in April of 2019, ∼1 month before admission to TJUH,
revealed a platelet count of 262,000 cells/mcL andwhite cell count
of 14,770 cells/mcL (48.1% lymphocytic). No plasma cells were
noted on the differential.
Given her mild leukocytosis in April of 2019, her physician
ordered a peripheral blood flow cytometry. The phenotypes
shown were a mixed population of maturing myeloid cells,
monocytes, eosinophils, B cells, and T cells. CD34 positive
blasts comprised 0.1% of the total nucleated cells. Monocytes
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TABLE 2 | Fluorescence in-situ Hybridization (FISH) result summary: including
multiple myeloma (MM) FISH panel on C138+ enriched plasma cells and
myeloproliferative neoplasm (MPN) panel on non-enriched unstimulated
non-plasma cells.
Positive findings for the CD138+ enriched
MM fish panel
Positive findings for the
MPN panel
Positive for loss of centromere 7 (CEP 7) Positive for deletion
5q−76%
Positive for typical and atypical translocations of
CCND1/IGH
Positive for loss of
centromere 7 (CEP7)−58%
Positive for rearrangement of IGH Positive for deletion BCR
(22q)−72.5%
Positive for deletion RB1 (13q) Positive for deletion RB1
(13q)−71.5%
Positive for deletion TP53 (17p) Negative for trisomy 8
Negative for deletion of 1p and gain of 1q
Negative for trisomy 7, trisomy 9, and trisomy 11
Negative for rearrangement of MYC
Percentages for MPN panel findings indicate percentage of nuclei positive for deletion.
and eosinophils comprised 4.7 and 1.6%, respectively. There
was no presence of a clonal plasma cell population (CD38
cell population).
One day prior to transfer to TJUH, in May 2019, the patient
presented to an outside hospital after a mechanical fall involving
her walker, resulting in a fracture of the left clavicle. A complete
blood cell count upon admission to TJUH showed a white cell
count of 60,900 cells/mcL with a manual differential indicating
60% plasma cells: ∼36,540 plasma cells/mcL (36.5 × 109/L),
well above 2 × 109/L plasma cells as per PCL diagnostic criteria
(Table 1). Peripheral blood flow cytometry showed a monoclonal
plasma cell population, comprising 70% of analyzed cells showing
the following phenotype: CD5−, CD10−, CD19−, CD20−,
CD22−, CD38+ (bright), CD138+, CD45−, CD56−, CD117−,
cytoplasmic kappa light chain+ (dim), and cytoplasmic lambda
light chain-. On bone marrow examination, the aspirate smear
showed sheets of plasma cells comprising 95% of all nucleated
cells with an overall hypercellular marrow of 90%. Of note, rare
megakaryocytes were seen. Fluorescence in-situ hybridization
(FISH) analysis revealed that the plasma cells were positive for
loss of centromere 7 (7q), typical and atypical translocations of
CCND1/IGH [(11;14)(q13.3;q32.3)], rearrangement of IGH gene
involving 14q32.3, deletion of RB1 (13q), and deletion of TP53
(17p); the MPN FISH panel on non-plasma cells was positive for
deletion 5q, loss of centromere 7 (7q), deletion of BCR (22q), and
deletion of Rb1 (13q) (Table 2).
In lateMay 2019, the patient underwent treatment with 1 cycle
of bortezomib, cyclophosphamide, and dexamethasone (VCD).
This was complicated by an admission for volume overload.
Her white blood cell count fell from 80,000 to 50,000 during
the first few days of treatment, but it was not completely
controlled. She was then switched to Dara-VCD. During cycle
1, she was admitted to the hospital for renal failure, during
which she became dialysis dependent. After 4 cycles of Dara-
VCD, her free kappa light chains decreased from 18,014 mg/L
to 8,394 mg/L by September 2019. She was ultimately taken off
dialysis. In mid-September, her free kappa light chains increased
to 9,396, requiring initiation of cycle 1 of dexamethasone,
cyclophosphamide, etoposide, and cisplatin (DCEP). This was
performed inpatient, and her free kappa light chains decreased
to 4305.2 mg/L. She then began treatment with carfilzomib,
lenalidomide, and dexamethasone (Krd) inOctober 2019. During
cycle 2, carfilzomib was lowered to 56 mg/m2 weekly. This cycle
was delayed due to admission for neutropenic fever. During
initiation of cycle 3, her free kappa decreased to 639 mg/L. For
cycle 4 in February 2020, her revlimid was held temporarily, but
restarted on day 11. She also had an admission for pneumonia.
Her free kappa light chains at this time were 774 mg/L. One
year after the patient’s initial presentation, the smear from a
repeat bone marrow examination inMarch 2020 showed residual
plasma cell myeloma/leukemia (∼10% marrow involvement).
JAK2 V617F mutation analysis was positive. She unfortunately
unexpectedly passed in lateMarch 2020while at home. A timeline
of her course is detailed in Figure 1.
DIAGNOSTIC ASSESSMENT
JAK2 Mutation Analysis
The laboratory test was performed at Integrated Oncology,
a business unit of Esoterix Genetics Laboratory, LLC, a
wholly owned subsidiary of Laboratory Corporation of America
Holdings. Genomic DNA was extracted and amplified by real-
time PCR using primers for the appropriate region of the JAK2
gene. The mutant and wild-type JAK2 sequences were detected
using specific fluorescent probes. The analytical sensitivity of the
assay is 1%: detection of 1 mutant copy of the JAK2 gene per 100
normal copies.
Fluorescence in-situ Hybridization (FISH)
Study: MM and MPN Panels
The MM FISH panel study was performed on CD138+ enriched
plasma cells; the MPN FISH study was performed on non-
enriched unstimulated cells, results of which likely represent
abnormalities from non-plasma cells or a mixture of different
cell populations. Probe sets from CytoTest, Inc. The cutoff value
for the 5q, 7q, BCR/ABL1 translocation, RB1, 17p13.1, 20q12,
IGH rearrangement, CCND1/IGH translocation, and MYC gene
rearrangement were <5, <6, <2, <8, <8, <7, <7, <2, and
<4%, respectively.
There were no overt diagnostic challenges in this case.
DISCUSSION
To our knowledge, this case is one of the few known reports
of a patient with a concomitant MPN and pPCL. The literature
of reported cases of patients with concomitant MPN and
plasma cell dyscrasias raises much interest, namely because
these malignancies originate from two separate cellular lineages
in hematopoiesis.
Given the literature demonstrating this phenomenon, it
has been proposed that in these instances of concomitant
malignancies, a common cellular origin might exist. Wang et al.
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FIGURE 1 | Timeline of patient’s course.
showed that bothmyeloid and lymphoid cells recovered fromBM
and spleens of mice with myelofibrosis both had positive JAK2
V617F mutations, suggesting the mutation occurred initially in
a common hematopoietic stem cell (HSC) (11). Some evidence
suggests that CML hematopoietic stem cell ancestry is shared
with lymphocyte stem cell ancestry of the B-cell lineage (12).
In addition, acute leukemia can be of mixed lineage origin or
even undergo lineage switch suggesting a common hematopoietic
stem cell (13). Hou et al. had found a novel human B cell/myeloid
common progenitor cell based on absence of CXC chemokine
receptor expression reinforcing the concept of shared ancestry
(14). A case of a woman with chronic lymphocytic leukemia
(CLL) and JAK-2 V617F mutation was reported showing that
the JAK2 mutation existed in the B lymphocytes, but not in
T lymphocytes. In this case, it was postulated that the JAK-
2 mutation was a secondary event to which a primary gene
mutation occurred at the common B lymphoid andmyeloid stem
cell—further suggesting the possibility of a common, pluripotent,
myeloid, and B lymphoid progenitor cell (15). Another report
assessing the presence of JAK2 V617F mutation in different cell
lines in eight patients with PV found that six of these patients
solely had the JAK2 mutation in the myeloid lineage of cells;
however, one PV patient was found to have the mutation present
in both B and T lymphocytes (as well as the myeloid cells), while
another PV patient was found to have the mutation present in
the B lymphocytes in addition tomyeloid cells (16). This indicates
that the JAK2mutation can occur as early as themultipotent HSC
level in some MPN cases.
On the FISH analysis utilizing a MM panel on the
patient’s plasma cells (Table 2), certain common chromosomal
abnormalities were present that are common in pPCL. Common
pPCL chromosomal abnormalities present included IgH
translocations, loss of 13q, and loss of 17p (TP53). For the
MPN FISH panel conducted, the deletion of 5q, 7q, and 13q
are chromosomal abnormalities notable in MPNs; 13q deletion
was also seen in the plasma cells, which is a deletion also
found to be prevalent in CLL, MM, and pPCL, as previously
mentioned (17). The positive deletion of 13q in the MPN panel
is less common for typical MPN chromosomal abnormalities
(17). The shared abnormalities on the FISH panel for the
plasma cells and non-plasma cells included the 13q deletion
and 7q deletion. Interestingly, the 7q deletion is not a typical
finding in pPCL FISH analysis, since it is more associated with
myeloid disorders (18, 19). The shared 7q deletion suggests
that the patient’s MPN and plasma cell leukemia may have
arisen from a common cellular origin. The 7q deletion, despite
being a predominantly myeloid chromosomal abnormality, is
also a prognosticator of poor outcome, especially for leukemic
transformation in MPN (20, 21).
There have, however, been studies published that argue
against the theory of a common cellular origin for these
two malignancies. Kuroda et al. showed independent genetic
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mutations in a patient with the coexistence of multiple myeloma
and ET; the JAK2 V617F was identified in peripheral white
blood cells and bone marrow-derived non-myeloma cells, but
not in CD138+ myeloma cells from the bone marrow (22).
Additionally, despite previously stated, there have been reports
of patients with concurrent CLL and JAK2 V617F positive MPN
that did not show the JAK2 mutation present in the lymphoid
cells (4). Overall, it appears there is mixed evidence in support
of a common cellular lineage for when these two separate
malignancies appear in the same patient; however, it remains
possible that in some instances of concomitantMPNs and plasma
cell dyscrasias, there might be a common cellular origin.
It is also possible that the bone marrow microenvironment
(BMM) could influence concomitant disease. Schofield first
demonstrated that bone marrow cells transplanted from wild-
type mice into W/Wv mice (mutation in kit) could continue
hematopoiesis indefinitely. In comparison, cells that formed
colonies in the spleen (colony-forming units-spleen cells) and
were subsequently transplanted lost that ability (23, 24). While
early studies focused on the role of the microenvironment in
promoting normal hematopoiesis, more recent data has shown
that alterations in the BMM may support malignant conditions
including MPNs and myeloid leukemia (25–27). Lundberg
et al. found that bone marrow vascularity was increased and
disorganized in patients with MPN and correlated with JAK-
2 burden (28). The endothelial cells of the BMM can also
be stimulated by proangiogenic and pro-inflammatory factors
to release VEGF, which causes increased blast survival and
proliferation (29, 30). Plasma cell interactions with the BMM
are not as well-studied, but there is evidence that various factors
secreted by endothelial cells and stromal cells affect myeloma
cell migration (26). While there are no specific studies in
relation to the BMM and concomitant disease from a myeloid
progenitor and lymphoid progenitor, it appears not unlikely
that these individually studied phenomena could coexist in the
described patient.
Speculation for the incidence of coexistence for these two
malignancies has also been focused on other shared precipitating
factors. Interleukin-6 (IL-6) has been postulated as a possible
culprit in certain instances linking the association of these
two malignancies. IL-6 is known as a promoter of platelet
production as well as being a player in the pathogenesis
of MM, given the fact that it is a potent human myeloma
cell growth factor (4). Radiation or drug exposure, namely
hydroxyurea, has been postulated as another shared precipitating
factor for both malignancies, although not relevant in this
particular case.
Strengths of this case report include its novelty, the availability
of patient data and ability to assess this patient’s outcome, and
its educational value. While there is a similar case detailed from
2004 of a patient from 1997, there is still value in reporting this
case, which is more than 15 years later. The patient detailed by
Candoni et al. had previous exposure to cytoreductive therapy
(hydroxyurea and busulphan), which may have contributed to
the development of PCL. Our patient was not started on any
similar treatment prior to her diagnosis of PCL. Further research
is needed in the association of these diseases to understand
whether these two cases reflect similar or divergent mechanisms
of pathogenesis. Limitations included the lack of literature of
this exact case given its novelty, which leads to an inability
to generalize. While previous associations between MPNs and
plasma cell dyscrasias have been noted in the literature, this is
one of the few published reports of a case of a concomitant JAK-
2 positive MPN and primary plasma cell leukemia. The exact
mechanism by which this phenomenon occurs remains under
debate due to their distinct lineages. As awareness of these cases
grows, our hope is that the understanding of these disease states
will be further elucidated.
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